CRISPR Therapeutics Stock News

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.

Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.

ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis

CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation. The approval of CASGEVY, the first CRISPR-based med

Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.

CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $71.96, marking a +0.69% move from the previous day.

CRISPR Therapeutics received important regulatory approvals last year. The company could make plenty of money on its lone marketed product.

Even with the wider market rebound, Cathie Wood hasn't quite recaptured her initial investment allure. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), remains a full two-thirds below its

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno